Pay in 4 interest-free payments of $6.23 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
The study CheckMate-025 (NCT01668784) 40 is a randomized, open-label, phase 3 study that evaluates PFS and OS in two treatment arms, nivolumab versus everolimus, in patients with advanced or metastatic clear-cell RCC with measurable disease according to the RECIST criteria (v.1.1) and after at least one anti-angiogenic therapy
Ready to get all five products and maximize your results
This article has been viewed 339,829 times
Glutathione, often dubbed the "master antioxidant," is a crucial molecule produced naturally within our cells
US$ 29.01
US$ 23.92
US$ 27.26
US$ 29.37
